Receive our newsletter – data, insights and analysis delivered to you
June 21, 2009

Vical sees Progress on RapidResponse DNA Vaccine Platform

Vical has received further funding to proceed with the development of its RapidResponse platform, designed to allow rapid and large-scale production of DNA vaccines with low capital requirements. The RapidResponse system will allow for the extremely rapid and large-scale production of D

By cms admin

Vical has received further funding to proceed with the development of its RapidResponse platform, designed to allow rapid and large-scale production of DNA vaccines with low capital requirements.

The RapidResponse system will allow for the extremely rapid and large-scale production of DNA vaccines, including those that affect large populations such as the H1N1 (swine flu) or H5N1 pandemic influenza or severe acute respiratory syndrome.

The third year of grant funding was awarded by the National Institute of Allergy and Infectious Diseases.

The company has completed significant second-year milestones under a three-year, $6m grant awarded in 2007, and is now advancing with the development of a DNA vaccine manufacturing process, to produce several million doses of vaccines in a matter of days.

The RapidResponse DNA vaccine manufacturing platform is intended to reduce the time required to develop, manufacture and deploy vaccines against emerging diseases during the early stages of an infectious outbreak.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU